Takeda Pharmaceutical Company Limited Cash Flow Conversion Efficiency
Takeda Pharmaceutical Company Limited cash flow conversion efficiency. Based on the latest financial reports, Takeda Pharmaceutical Company Limited (TKDA) has a cash flow conversion efficiency ratio of 0.049x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€373.25 Billion ≈ $436.37 Billion USD) by net assets (€7.64 Trillion ≈ $8.94 Trillion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Takeda Pharmaceutical Company Limited worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Takeda Pharmaceutical Company Limited (2017–2025)
Cash flow conversion efficiency of Takeda Pharmaceutical Company Limited from 2017 to 2025. This chart illustrates how Takeda Pharmaceutical Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Takeda Pharmaceutical Company Limited share price for real-time trading data and today's change.
Takeda Pharmaceutical Company Limited Cash Flow Conversion Ratio Explained
Takeda Pharmaceutical Company Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Takeda Pharmaceutical Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Takeda Pharmaceutical Company Limited ranked by their cash flow conversion efficiency. Review TKDA free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haleon plc
NYSE:HLN
|
0.055x |
|
Coca-Cola European Partners PLC
NASDAQ:CCEP
|
0.116x |
|
Agilent Technologies Inc
NYSE:A
|
0.054x |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
0.080x |
|
STANDARD CHART.UNSP.ADR/2
F:STD0
|
N/A |
|
Danske Bank A/S
CO:DANSKE
|
-0.020x |
|
Siemens Healthineers AG
F:SHL
|
0.064x |
|
Cardinal Health Inc
NYSE:CAH
|
-0.682x |
Annual Cash Flow Conversion Efficiency for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Takeda Pharmaceutical Company Limited from 2017 to 2025. Also see Takeda Pharmaceutical Company Limited balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €6.94 Trillion ≈ $8.11 Trillion |
€1.06 Trillion ≈ $1.24 Trillion |
0.152x | +54.77% |
| 2024-03-31 | €7.27 Trillion ≈ $8.50 Trillion |
€716.34 Billion ≈ $837.48 Billion |
0.098x | -35.96% |
| 2023-03-31 | €6.35 Trillion ≈ $7.43 Trillion |
€977.16 Billion ≈ $1.14 Trillion |
0.154x | -22.18% |
| 2022-03-31 | €5.68 Trillion ≈ $6.64 Trillion |
€1.12 Trillion ≈ $1.31 Trillion |
0.198x | +1.20% |
| 2021-03-31 | €5.18 Trillion ≈ $6.05 Trillion |
€1.01 Trillion ≈ $1.18 Trillion |
0.195x | +37.83% |
| 2020-03-31 | €4.73 Trillion ≈ $5.53 Trillion |
€669.75 Billion ≈ $783.01 Billion |
0.142x | +122.70% |
| 2019-03-31 | €5.16 Trillion ≈ $6.04 Trillion |
€328.48 Billion ≈ $384.03 Billion |
0.064x | -66.04% |
| 2018-03-31 | €2.02 Trillion ≈ $2.36 Trillion |
€377.85 Billion ≈ $441.75 Billion |
0.187x | +39.67% |
| 2017-03-31 | €1.95 Trillion ≈ $2.28 Trillion |
€261.36 Billion ≈ $305.56 Billion |
0.134x | -- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more